OBJECTIVE:To comprehensively evaluate the safety

efficacy and economy of Qishen Yiqi dropping pills in the treatment of chronic heart failure based on evidence-based evidence

so as to provide evidence-based pharmacoeconomics basis for clinical treatment.METHODS:PubMed

EMBase

the Cochrane library

Clinical trials.gov

CNKI

VIP database and Wanfang database were retrieved to collect randomized controlled trials（RCT） of Qishen Yiqi dropping pills（the research group was given Qishen Yiqi dropping pills on the basis of routine anti-heart failure treatment） and conventional anti-heart failure drugs（the control group received conventional anti-heart failure therapy） in the treatment of chronic heart failure.After literature screening and data extraction

Review Manager 5.3 software was used for Meta-analysis.Pharmacoeconomic evaluation was performed with efficacy

safety and economy.RESULTS:Totally 27 literature was collected

including 3 893 patients.Meta-analysis results showed that the total effective rate of improvement of cardiac function in the research group was significantly higher than that in the control group

and the difference was statistically significant（RR=1.20

95%CI=1.16-1.23

P<0.000 01）.Compared with the control group

the treatment regimen of the research group can significantly improve patients’left ventricular ejection fraction（MD=6.79

95% CI=6.50-7.07

P <0·000 01）

6 min walking distance（MD=45.08

95% CI=43.09-47.08

P<0.000 01） and brain natriuretic peptide content（MD=-108.51

95% CI=-112.54--104.49

P<0.000 01）

the difference was statistically significant.The incidence of adverse drug reactions（abnormal liver and kidney function

nausea and cough） was not significantly different between two groups（P>0.05）.Cost-effectiveness analysis showed that the incremental cost-effectiveness ratio was 2 503.03.CONCLUSIONS:Compared with conventional anti-heart failure drugs

Qishen Yiqi dropping pills can significantly improve the effective rate

left ventricular ebitus fraction

6 min walking distance and the content of blood brain natriuretic peptide in patients with chronic heart failure.Each additional effect will cost more 2 503.03 yuan

the treatment regimen can be selected according to patients ’own willingness to pay in clinical treatment.